Hanall Biopharma (009420) — Cash Flow Reinvestment Rate
Hanall Biopharma (009420) has a Cash Flow Reinvestment Rate of 0.45x as of September 2025, reinvesting ₩3.27 Billion (capex ₩3.27 Billion ) from operating cash flow of ₩7.34 Billion. Explore reinvestment intensity of Hanall Biopharma to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hanall Biopharma Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for Hanall Biopharma across 10 annual periods. Also explore Hanall Biopharma balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Hanall Biopharma (2011–2024)
Year-by-year capital reinvestment analysis for Hanall Biopharma. For live market cap and broader valuation context, see market cap of Hanall Biopharma.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.80x | ₩26.19 Billion | ₩9.36 Billion | ₩23.07 Billion | ▲ +293.4% |
| 2023 | 0.71x | ₩21.08 Billion | ₩29.64 Billion | ₩9.20 Billion | ▲ +211.1% |
| 2022 | 0.23x | ₩5.76 Billion | ₩25.20 Billion | ₩2.83 Billion | ▼ -99.1% |
| 2021 | 25.62x | ₩21.52 Billion | ₩839.87 Million | ₩4.61 Billion | ▲ +211.9% |
| 2020 | 8.21x | ₩7.63 Billion | ₩929.29 Million | ₩2.56 Billion | ▲ +452.7% |
| 2019 | 1.49x | ₩30.45 Billion | ₩20.49 Billion | ₩2.12 Billion | ▲ +533.8% |
| 2017 | 0.23x | ₩9.88 Billion | ₩42.14 Billion | ₩1.73 Billion | ▼ -93.8% |
| 2016 | 3.76x | ₩14.84 Billion | ₩3.95 Billion | ₩4.03 Billion | ▲ +277.6% |
| 2012 | 0.99x | ₩2.18 Billion | ₩2.20 Billion | ₩2.18 Billion | ▲ +1627.8% |
| 2011 | 0.06x | ₩426.70 Million | ₩7.41 Billion | ₩426.70 Million | — |